Sign Up Today and Learn More About PhaseBio Pharmaceuticals Stock
Invest in or calculate the value of your shares in PhaseBio Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
PhaseBio Pharmaceuticals Stock
Developing drugs for cardiovascular diseases, endocrine and metabolic disorders
About PhaseBio Pharmaceuticals Stock
Founded
2002
Headquarters
Malvern, PA, US
Total Funding
140M
Industries
Software, Artificial Intelligence, Data and Analytics
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance. Efficient production in E. coli ensures low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. A second drug candidate, Vasomera™, is currently being evaluated in a phase 1 clinical trial and has potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. A third program, Insumera, a basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals Management
Leadership team at PhaseBio Pharmaceuticals
CEO
Christopher Prior
Executive Chairman & CSO
Craig A. Rosen
Join now and verify your accreditation status to gain access to:
- PhaseBio Pharmaceuticals current valuation
- PhaseBio Pharmaceuticals stock price
- Available deals in PhaseBio Pharmaceuticals and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in PhaseBio Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like PhaseBio Pharmaceuticals through EquityZen funds. These investments are made available by existing PhaseBio Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell PhaseBio Pharmaceuticals stock?
Shareholders can sell their PhaseBio Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
